Another study showed that TrkB, as a high-affinity receptor for BDNF and NT-4, is highly expressed in HNSCC and that TrkB receptor blockers can inhibit the proliferation of cancer cells in vitro (Kupferman et al., 2010; Dudás et al., 2011). Here, BDNF is linked to head and neck squamous cell carcinoma.